FzioMed Oxiplex Dispute Panel Postponed So CDRH Can Review More Data
This article was originally published in The Gray Sheet
Executive Summary
With more data submitted to CDRH, FzioMed and the device center have agreed to postpone a planned June 10 dispute-resolution panel meeting on the firm’s previously rejected PMA for the Oxiplex spine surgery gel.
You may also be interested in...
FDA To Accept Wright’s PMA Amendment For Augment Bone Graft
The agency has agreed to accept Wright Medical’s PMA amendment for its embattled Augment bone graft, saving the firm from going to a dispute resolution panel this spring.
FzioMed Gets Second Chance For Oxiplex Gel PMA With Dispute Resolution Panel
FDA granted FzioMed’s petition for an independent review of its Oxiplex gel PMA by the Medical Devices Dispute Resolution Panel in response to FzioMed’s November 2012 petition. The agency deemed the device, intended for use in spine surgery, as “not approvable” in 2008.
FzioMed Oxiplex Anti-Adhesion Gel Not Approvable For Spine Surgery – Panel
FzioMed's Oxiplex/SP anti-adhesion gel for spine surgery is "not approvable" due to its failure to adequately demonstrate a statistically significant treatment benefit in the sponsor's randomized, pivotal trial, according to FDA's Orthopaedic and Rehabilitation Devices Panel